Flow Neuroscience (FL-100)

Overview

The Flow Neuroscience FL-100 is the first and currently only at-home, non-drug brain-stimulation therapy with FDA premarket approval (PMA P230024, December 2025) for major depressive disorder in the US. Flow operates in a different regulatory category than the rest of consumer tDCS: while Caputron, foc.us, theBrainDriver, and PlatoScience all market under general-wellness for cognitive enhancement, Flow holds a PMA for treating MDD — the highest-rigor FDA pathway available for medical devices.

The 2026 tDCS landscape sits at the inflection where PMA approval restructures the editorial frame. Flow is no longer “a consumer tDCS product”; it’s a prescription-gated medical device that happens to be self-administered at home. Comparisons against consumer-wellness tDCS are valid for technology comparison but misleading for use-case comparison.

What We Measured

Note: This review is based on the FDA PMA P230024 file, the published Nature Medicine RCT (n=174), Flow’s published real-world treatment data, and consumer-reported app and support experience. Hands-on current-output verification (digital multimeter), session-protocol consistency, and electrode-contact reliability are pending.

Clinical evidence — Nature Medicine RCT

Flow’s pivotal trial was a sham-controlled, double-blind RCT with n=174 participants, published in Nature Medicine. The trial supported the FDA PMA submission and demonstrated significant antidepressant effect vs sham. Sample size, blinding, primary endpoint, and statistical analysis are publicly available in the published paper — the strongest evidence base for any at-home tDCS device, by a wide margin over consumer competitors.

Real-world treatment data

Post-launch data published by Flow reports:

• 77% clinical improvement (≥50% reduction in MADRS score) across treatment courses
• 57% remission (MADRS ≤ 9)

These are aggregate real-world outcomes — distinct from the controlled-trial data. Both are consistent with the published trial’s effect size; they reinforce that the device performs in unselected patient populations as well as in the registration trial.

Stimulation parameters

The FL-100 delivers 2 mA tDCS to the dorsolateral prefrontal cortex (DLPFC) — anode placement on the left DLPFC, cathode on the right DLPFC. Sessions are 30 minutes, typically 5× per week for the first 3 weeks, then 2–3× per week through week 10. The protocol is fixed by the FDA-cleared course; the device is not user-programmable.

Companion app

Bluetooth pairing with a Flow app running on iOS/Android. The app delivers structured guided sessions including behavioral therapy content. Some users describe the in-session guidance as overly simplified; others find it appropriate for users new to tDCS. App-store ratings: 4.4 iOS, 3.9 Android.

Side-effect profile

Most-reported side effects, consistent with the published trial: skin sensation under electrodes (burning, tingling) on a percentage of users; headache after sessions on a smaller percentage; rare worsening of mood during the early protocol period (which is also seen with antidepressant initiation).

3-Year Cost of Ownership

Component	Cost
Flow FL-100 device + initial 10-week protocol	~$500–$800
Subscription / refills for ongoing use	varies by prescriber
Initial course (10 weeks)	~$500–$800

Compare: Caputron Activadose Starter Kit ($300 consumer wellness — different category), foc.us v3 / Go Flow ($200 consumer wellness), professional clinic-administered tDCS (~$200/session × 20 sessions = $4,000+).

Flow’s pricing is at the consumer-tDCS top end but well below clinic-administered tDCS — and it’s the only at-home option with PMA approval for the depression indication.

Regulatory Status

FDA PMA Cleared (P230024, December 2025). PMA is the most rigorous FDA pathway for medical devices — substantively higher than 510(k). PMA requires safety AND efficacy evidence reviewed and approved by FDA. Flow is the only consumer-distributed tDCS device to hold a PMA for the major depressive disorder indication.

Verifiable directly on accessdata.fda.gov by searching the PMA number. This is the regulatory position that separates Flow from every other consumer tDCS — competitors operate under general-wellness policy without disease-treatment claims.

When Flow Makes Sense — And When It Doesn’t

Strong fit:

• You have moderate-to-severe major depressive disorder and a prescriber willing to evaluate Flow.
• You’re seeking a non-drug or adjunct-to-drug option with the strongest evidence base.
• You’re comfortable with the prescription-gated pathway and the structured 10-week protocol.

Weaker fit:

• You want tDCS for cognitive enhancement, focus, or general wellness — Flow is not approved for those uses, and consumer-wellness tDCS (Caputron, foc.us) is the appropriate product class.
• You’re not comfortable with prescription gating and the prescriber relationship.
• You can’t tolerate the protocol commitment (30 min × 5 days/week for 3 weeks).

Verdict: Recommended

Flow Neuroscience FL-100 earns the recommendation as the only FDA-PMA approved at-home tDCS for major depressive disorder. The Nature Medicine RCT, real-world 77%/57% improvement-and-remission data, and PMA regulatory position are unique in consumer neurostimulation. For depression patients with a willing prescriber, this is the most evidence-supported at-home option available.

The recommendation is conditional on use case: Flow is for treating depression, not for cognitive enhancement, focus, or general wellness. Buyers seeking the latter should evaluate consumer-wellness tDCS as a separate product class.

App guidance and customer-support friction are real but minor compared to the underlying clinical and regulatory position.

Changelog

• 2026-05-05: Initial review published based on FDA PMA P230024 file, Nature Medicine RCT, and Flow’s published real-world data. Hands-on current-output testing pending.